** Shares of telehealth firm Hims & Hers HIMS.N fall 6.2% to $37.98 premarket
** Novo Nordisk NOVOb.CO says it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash paying customers in the United States
** Wegovy has a list price of around $1,350 a month, regardless of dosage
** Discounted drugs will be distributed through a program called NovoCare Pharmacy to uninsured patients or those whose insurance does not cover obesity medicines
** HIMS has benefited from selling cheaper copies, or compounded versions, of Wegovy
** Telehealth firm's shares have nearly tripled in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.